Cue Biopharma (CUE) Expected to Post Earnings on Tuesday

Cue Biopharma (NASDAQ:CUE) will likely be posting its Q2 2026 results before the market opens on Tuesday, August 18th. Analysts expect Cue Biopharma to post earnings of ($1.69) per share and revenue of $3.00 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Wednesday, August 19, 2026 at 4:00 PM ET.

Cue Biopharma (NASDAQ:CUE) last released its quarterly earnings data on Thursday, May 14th. The company reported ($1.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.30) by $2.22. Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 98.30%. The firm had revenue of $5.69 million for the quarter, compared to analysts’ expectations of $2.50 million.

Cue Biopharma Stock Performance

CUE stock opened at $26.10 on Tuesday. The company’s fifty day moving average price is $29.31 and its 200-day moving average price is $154.54. Cue Biopharma has a one year low of $4.97 and a one year high of $45.50. The company has a market capitalization of $109.62 million, a PE ratio of -4.67 and a beta of 2.47.

Hedge Funds Weigh In On Cue Biopharma

Several large investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. raised its holdings in Cue Biopharma by 730.0% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock valued at $57,000 after buying an additional 73,000 shares during the period. Squarepoint Ops LLC bought a new stake in Cue Biopharma in the third quarter worth $62,000. Boothbay Fund Management LLC purchased a new position in Cue Biopharma during the third quarter worth $439,000. Finally, Stifel Financial Corp boosted its stake in Cue Biopharma by 25.4% during the fourth quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after buying an additional 50,000 shares during the period. Institutional investors own 35.04% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Weiss Ratings upgraded shares of Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 18th. Wall Street Zen upgraded Cue Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Cue Biopharma presently has a consensus rating of “Sell”.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.